Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial

PRNewswire NATICK, Mass. (NYSE:BSX)

NATICK, Mass., Aug. 24 /<u>PRNewswire-FirstCall</u>/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing final results from the landmark MADIT-CRT trial on Tuesday, September 1, at 8:00 a.m. ET / 2:00 p.m. Barcelona time.

The call will be hosted by Ray Elliott, President and Chief Executive Officer; Fred Colen, Executive Vice President and Group President, Cardiac Rhythm Management; and Arthur Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the trial.

The final results from the MADIT-CRT trial will be presented during a Hot Line session at the European Society of Cardiology (ESC) Congress in Barcelona and published in a major peer-reviewed journal. The Company plans to issue a press release simultaneous with an ESC Hot Line press conference to be held in Barcelona on September 1.

The live webcast and archived replay of this call will be available at<u>www.bostonscientific.com</u> in the Investor Relations section. The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: <u>www.earnings.com</u>, which is accessible to the public, and <u>www.streetevents.com</u>, a passwordprotected event management site.

To ensure a timely connection to the live webcast it is recommended that users register at least 15 minutes before the webcast begins. A replay of the webcast will begin at approximately 11:00 a.m. ET on September 1 and will be available for one year.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

CONTACT: Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation

> Larry Neumann 508-650-8696 Investor Relations Boston Scientific Corporation

SOURCE Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

https://news.bostonscientific.com/news-releases?item=59170